HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.
HSF1
Intrahepatic cholangiocarcinoma
KRIBB-11
Mouse models
Navitoclax
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
received:
13
06
2024
accepted:
29
08
2024
medline:
7
9
2024
pubmed:
7
9
2024
entrez:
6
9
2024
Statut:
epublish
Résumé
Intrahepatic cholangiocarcinoma (iCCA) is a lethal primary liver tumor characterized by clinical aggressiveness, poor prognosis, and scarce therapeutic possibilities. Therefore, new treatments are urgently needed to render this disease curable. Since cumulating evidence supports the oncogenic properties of the Heat Shock Factor 1 (HSF1) transcription factor in various cancer types, we investigated its pathogenetic and therapeutic relevance in iCCA. Levels of HSF1 were evaluated in a vast collection of iCCA specimens. The effects of HSF1 inactivation on iCCA development in vivo were investigated using three established oncogene-driven iCCA mouse models. In addition, the impact of HSF1 suppression on tumor cells and tumor stroma was assessed in iCCA cell lines, human iCCA cancer-associated fibroblasts (hCAFs), and patient-derived organoids. Human preinvasive, invasive, and metastatic iCCAs displayed widespread HSF1 upregulation, which was associated with a dismal prognosis of the patients. In addition, hydrodynamic injection of a dominant-negative form of HSF1 (HSF1dn), which suppresses HSF1 activity, significantly delayed cholangiocarcinogenesis in AKT/NICD, AKT/YAP, and AKT/TAZ mice. In iCCA cell lines, iCCA hCAFs, and patient-derived organoids, administration of the HSF1 inhibitor KRIBB-11 significantly reduced proliferation and induced apoptosis. Cell death was profoundly augmented by concomitant administration of the Bcl-xL/Bcl2/Bcl-w inhibitor ABT-263. Furthermore, KRIBB-11 reduced mitochondrial bioenergetics and glycolysis of iCCA cells. The present data underscore the critical pathogenetic, prognostic, and therapeutic role of HSF1 in cholangiocarcinogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Intrahepatic cholangiocarcinoma (iCCA) is a lethal primary liver tumor characterized by clinical aggressiveness, poor prognosis, and scarce therapeutic possibilities. Therefore, new treatments are urgently needed to render this disease curable. Since cumulating evidence supports the oncogenic properties of the Heat Shock Factor 1 (HSF1) transcription factor in various cancer types, we investigated its pathogenetic and therapeutic relevance in iCCA.
METHODS
METHODS
Levels of HSF1 were evaluated in a vast collection of iCCA specimens. The effects of HSF1 inactivation on iCCA development in vivo were investigated using three established oncogene-driven iCCA mouse models. In addition, the impact of HSF1 suppression on tumor cells and tumor stroma was assessed in iCCA cell lines, human iCCA cancer-associated fibroblasts (hCAFs), and patient-derived organoids.
RESULTS
RESULTS
Human preinvasive, invasive, and metastatic iCCAs displayed widespread HSF1 upregulation, which was associated with a dismal prognosis of the patients. In addition, hydrodynamic injection of a dominant-negative form of HSF1 (HSF1dn), which suppresses HSF1 activity, significantly delayed cholangiocarcinogenesis in AKT/NICD, AKT/YAP, and AKT/TAZ mice. In iCCA cell lines, iCCA hCAFs, and patient-derived organoids, administration of the HSF1 inhibitor KRIBB-11 significantly reduced proliferation and induced apoptosis. Cell death was profoundly augmented by concomitant administration of the Bcl-xL/Bcl2/Bcl-w inhibitor ABT-263. Furthermore, KRIBB-11 reduced mitochondrial bioenergetics and glycolysis of iCCA cells.
CONCLUSIONS
CONCLUSIONS
The present data underscore the critical pathogenetic, prognostic, and therapeutic role of HSF1 in cholangiocarcinogenesis.
Identifiants
pubmed: 39243039
doi: 10.1186/s13046-024-03177-7
pii: 10.1186/s13046-024-03177-7
doi:
Substances chimiques
Heat Shock Transcription Factors
0
HSF1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Informations de copyright
© 2024. The Author(s).
Références
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80.
doi: 10.1038/nrgastro.2016.51
pubmed: 27095655
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–88.
doi: 10.1038/s41575-020-0310-z
pubmed: 32606456
pmcid: 7447603
Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111.
doi: 10.1038/nrclinonc.2017.157
pubmed: 28994423
El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28:587–99.
doi: 10.1016/j.soc.2019.06.002
pubmed: 31472907
Acher AW, Paro A, Elfadaly A, Tsilimigras D, Pawlik TM. Intrahepatic cholangiocarcinoma: a summative review of biomarkers and targeted therapies. Cancers. 2021;13:5169.
doi: 10.3390/cancers13205169
pubmed: 34680318
pmcid: 8533913
Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:349–65.
doi: 10.1038/s41575-022-00741-4
pubmed: 36697706
Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25:626–35.
doi: 10.1016/S1470-2045(24)00082-2
pubmed: 38697156
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853–65.
doi: 10.1016/S0140-6736(23)00727-4
pubmed: 37075781
Carpenter RL, Gökmen-Polar Y. HSF1 as a cancer biomarker and therapeutic target. Curr Cancer Drug Targets. 2019;19:515–24.
doi: 10.2174/1568009618666181018162117
pubmed: 30338738
pmcid: 6472998
Dai C. The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis. Philos Trans R Soc Lond B Biol Sci. 2018;373:20160525.
doi: 10.1098/rstb.2016.0525
pubmed: 29203710
Jiang S, Tu K, Fu Q, Schmitt DC, Zhou L, Lu N, et al. Multifaceted roles of HSF1 in cancer. Tumour Biol. 2015;36:4923–31.
doi: 10.1007/s13277-015-3674-x
pubmed: 26108999
Xu M, Lin L, Ram BM, Shriwas O, Chuang KH, Dai S, et al. Heat shock factor 1 (HSF1) specifically potentiates c-MYC-mediated transcription independently of the canonical heat shock response. Cell Rep. 2023;42: 112557.
doi: 10.1016/j.celrep.2023.112557
pubmed: 37224019
pmcid: 10592515
Dai B, Gong A, Jing Z, Aldape KD, Kang SH, Sawaya R, et al. Forkhead box M1 is regulated by heat shock factor 1 and promotes glioma cells survival under heat shock stress. J Biol Chem. 2013;288:1634–42.
doi: 10.1074/jbc.M112.379362
pubmed: 23192351
Jin X, Moskophidis D, Mivechi NF. Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab. 2011;14:91–103.
doi: 10.1016/j.cmet.2011.03.025
pubmed: 21723507
pmcid: 3214631
Chuma M, Sakamoto N, Nakai A, Hige S, Nakanishi M, Natsuizaka M, et al. Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-κB/mitogen-activated protein kinase. Carcinogenesis. 2014;35:272–81.
doi: 10.1093/carcin/bgt343
pubmed: 24130164
Li S, Ma W, Fei T, Lou Q, Zhang Y, Cui X, et al. Upregulation of heat shock factor 1 transcription activity is associated with hepatocellular carcinoma progression. Mol Med Rep. 2014;10:2313–21.
doi: 10.3892/mmr.2014.2547
pubmed: 25199534
pmcid: 4214332
Kawashita Y, Morine Y, Saito Y, Takasu C, Ikemoto T, Iwahashi S, et al. Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas. J Gastroenterol Hepatol. 2018;33:1407–12.
doi: 10.1111/jgh.14078
pubmed: 29278438
Dudeja V, Chugh RK, Sangwan V, Skube SJ, Mujumdar NR, Antonoff MB, et al. Prosurvival role of heat shock factor 1 in the pathogenesis of pancreatobiliary tumors. Am J Physiol Gastrointest Liver Physiol. 2011;300:G948–55.
doi: 10.1152/ajpgi.00346.2010
pubmed: 21330448
pmcid: 3307520
Cigliano A, Wang C, Pilo MG, Szydlowska M, Brozzetti S, Latte G, et al. Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice. Oncotarget. 2017;8:54149–59.
doi: 10.18632/oncotarget.16927
pubmed: 28903330
pmcid: 5589569
Cigliano A, Pilo MG, Li L, Latte G, Szydlowska M, Simile MM, et al. Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget. 2017;8:90638–50.
doi: 10.18632/oncotarget.21469
pubmed: 29207593
pmcid: 5710874
Wang Y, Theriault JR, He H, Gong J, Calderwood SK. Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells. J Biol Chem. 2004;279:32651–9.
doi: 10.1074/jbc.M401475200
pubmed: 15152009
Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122:2911–5.
doi: 10.1172/JCI63212
pubmed: 22797301
pmcid: 3408746
Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, et al. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017;67(6):1194–203.
doi: 10.1016/j.jhep.2017.07.006
pubmed: 28733220
pmcid: 5696057
Cigliano A, Zhang S, Ribback S, Steinmann S, Sini M, Ament CE, et al. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. J Exp Clin Cancer Res. 2022;41:192.
doi: 10.1186/s13046-022-02394-2
pubmed: 35655220
pmcid: 9164528
Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014;184:912–23.
doi: 10.1016/j.ajpath.2013.12.002
pubmed: 24480331
pmcid: 3969989
Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140:1071–83.
doi: 10.1053/j.gastro.2010.12.006
pubmed: 21147110
Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014;158:564–78.
doi: 10.1016/j.cell.2014.05.045
pubmed: 25083868
pmcid: 4249939
Grunberg N, Levi-Galibov O, Scherz-Shouval R. The role of HSF1 and the chaperone network in the tumor microenvironment. Adv Exp Med Biol. 2020;1243:101–11.
doi: 10.1007/978-3-030-40204-4_7
pubmed: 32297214
Grunberg N, Pevsner-Fischer M, Goshen-Lago T, Diment J, Stein Y, Lavon H, et al. Cancer-associated fibroblasts promote aggressive gastric cancer phenotypes via heat shock factor 1-mediated secretion of extracellular vesicles. Cancer Res. 2021;81:1639–53.
doi: 10.1158/0008-5472.CAN-20-2756
pubmed: 33547159
pmcid: 8337092
Shi Y, Sun L, Zhang R, Hu Y, Wu Y, Dong X, et al. Thrombospondin 4/integrin alpha2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells. J Exp Clin Cancer Res. 2021;40(1):14.
doi: 10.1186/s13046-020-01812-7
pubmed: 33407730
pmcid: 7789630
Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013;73(2):897–907.
doi: 10.1158/0008-5472.CAN-12-2130
pubmed: 23221385
Tanaka N, Okada H, Yamaguchi K, Seki M, Matsubara D, Gotoh N, et al. Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation. Cell Death Dis. 2023;14:815.
doi: 10.1038/s41419-023-06352-4
pubmed: 38081808
pmcid: 10713533
Liao Y, Xue Y, Zhang L, Feng X, Liu W, Zhang G. Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients. J Transl Med. 2015;13:338.
doi: 10.1186/s12967-015-0703-x
pubmed: 26511079
pmcid: 4625739
Nikotina AD, Vladimirova SA, Kokoreva NE, Nevdakha VA, Lazarev VF, Kuznetcova LS, et al. Novel mechanism of drug resistance triggered by tumor-associated macrophages through Heat Shock Factor-1 activation. Cancer Immunol Immunother. 2024;73(2):25.
doi: 10.1007/s00262-023-03612-2
pubmed: 38280079
pmcid: 10821977
Liu HT, Huang DA, Li MM, Liu HD, Guo K. HSF1: a mediator in metabolic alteration of hepatocellular carcinoma cells in crosstalking with tumor-associated macrophages. Am J Transl Res. 2019;11:5054–64.
pubmed: 31497221
pmcid: 6731433
Huang M, Dong W, Xie R, Wu J, Su Q, Li W, et al. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program. Cancer Commun. 2022;42:447–70.
doi: 10.1002/cac2.12284
Hahn JS, Hu Z, Thiele DJ, Iyer VR. Genome-wide analysis of the biology of stress responses through heat shock transcription factor. Mol Cell Biol. 2004;24:5249–56.
doi: 10.1128/MCB.24.12.5249-5256.2004
pubmed: 15169889
pmcid: 419887